Evaluation of FLIPR Calcium 3 Assay Kit—A New No-Wash Fluorescence Calcium Indicator Reagent

Abstract

We have evaluated the FLIPR Calcium 3 Assay Kit (Calcium 3), a new no-wash fluorescence calcium indicator dye reagent, for the measurement of agonist-stimulated calcium signaling in cells expressing the serotonin 2C (5-HT_2C), metabotropic glutamate receptor 5 (mGluR5) and the vasopressin 2 (V2) G-protein-coupled receptors. Calcium 3 yielded equivalent (5-HT_2C) or superior (mGluR5 and V2) sensitivity to FLUO-4 as indexed by the change in fluorescence counts following agonist application. Assay variability, indexed by CV, using Calcium 3 or FLUO-4 was equivalent with 5-HT_2C receptor responses although CVs were reduced using Calcium 3 in the examples of the mGluR5 and V2 receptors. Receptor pharmacologies based on agonist EC₅₀ values were identical when either Calcium 3 or FLUO-4 were utilized. Our results validate Calcium 3 as a compel-ling alternative to FLUO-4 in the choice of fluorescent dye reagent for studying G-protein-coupled receptors, providing the advantage of a homogenous, no-wash assay format. (Journal of Biomolecular Screening 2003:571-577)

References

1. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca indicators with greatly improved fluorescence properties . J Biol Chem 1985;260: 3440-3450 .

2. Minta A, Kao JP, Tsien RY: Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores . J Biol Chem 1989;264: 8171-8178 .

3. Gee KR, Brown KA, Chen WN, Bishop-Stewart J, Gray D, Johnson I: Chemical and physiological characterization of fluo-4 Ca-indicator dyes . Cell Calcium 2000;27: 97-106 .

4. US patent 6,420,183. Masking background fluorescence and luminescence in optical analysis of biomedical assays.

5. Porter RHP, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, et al: 1999. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT receptors in CHO-K1 cells . Br J Pharmacol 128: 13-20 .

6. Jerman JC, Brough SJ, Gager T, Wood M, Coldwell MC, Smart D, et al: Pharmacological characterization of human 5-HT2 receptor subtypes . Eur J Pharmacol 2001;414: 23-30 .

7. Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, et al: Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell line using FLIPR . Br J Pharmacol 1999;128: 1-3 .

8. Smart D, Jerman JC, Brough SJ, Neville WA, Jewitt F, Porter RA: The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors . Br J Pharmacol 2000;129: 1289-1291 .

9. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA: SB-334867-A: the first selective orexin-1 receptor antagonist . Br J Pharmacol 2001;132: 1179-1182 .

10.

10. Miller TR, Witte DG, Ireland LM, Kang CH, Roch JM, Masters JN, et al: Analysis of apparent noncompetitive responses to competitive H1 histamine receptor antagonists in fluorescent imaging plate reader based calcium assays . J Biomol Screen 1999;4: 249-258 .

11.

11. Simpson PB, Woollacott AJ, Hill RG, Seabrook GR: Functional characterization of bradykinin analogs on recombinant human bradykinin B-1 and B-2 receptors . Eur J Pharmacol 2000;392: 1-9 .

12.

12. Brough SJ, Jerman JC, Jewitt F, Smart D: Characterization of an endogenous bombesin receptor in CHO/DG44 cells . Eur J Pharmacol 2000;409: 259-263 .

13.

13. Patel K, Barnes A, Camacho J, Paterson C, Boughtflower R, Cousens D, et al: Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells . Eur J Pharmacol 2001;430: 203-210 .

14.

14. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) . Br J Pharmacol 2000;129: 227-230 .

15.

15. Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, Cairns Wet al: Characterization using FLIPR of human vanilloid receptor pharmacology . Eur J Pharmacol 2001;417: 51-58 .

16.

16. Coward P, Chan SDH, Wada HG, Humphries GM, Conklin BR: Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors . Anal Biochem 1999;270: 242-248 .

17.

17. Zhang Y, Nawoschik S, Kowal D, Smith D, Ochalski R, Schechter L, et al: Functional characterization of the 5-HT receptor coupled to calcium signaling using an enabling chimeric G-protein . Soc Neurosci Abstr 2001;27: 2656 .

18.

18. Wood M, Chaubey M, Atkinson P, Thomas DR: Antagonist activity of metachlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT7 receptor . Eur J Pharmacol 2000;396: 1-8 .

19.

19. Wood MD, Murkitt KL, Rice SQ, Testa T, Punia PK, Stammers M, et al: The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen . Br J Pharmacol 2000;131: 1050-1054 .

20.

20. Uvegas AJ, Kowal D, Zhang Y, Spangler TB, Dunlop J, Semus S, et al: The role of transmembrane helix 5 in agonist binding to the human H3 receptor . J Pharmacol Exp Ther 2002;301: 451-458 .

21.

21. Kowal DM, Nawoschik S, Ochalski R, Dunlop J: A functional characterization and comparison of agonist activities at human mGlu receptors 2 and 4 co-expressed with a calcium pathway facilitating G-protein chimera in CHO cells . Neuropharmacology 2002;43: 293, #72 .